key: cord-1014599-4470ftbk authors: Egloff, Charles; Vauloup-Fellous, Christelle; Picone, Olivier; Mandelbrot, Laurent; Roques, Pierre title: Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2 date: 2020-05-18 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104447 sha: 71f90deef74e7431da15982d9819530c4bbb03d4 doc_id: 1014599 cord_uid: 4470ftbk While SARS-CoV-2 infection has spread rapidly worldwide, data remains scarce about the natural history of infection in pregnant women and the risk of mother-to-fetal transmission. Current data indicates that viral RNA levels in maternal blood are low and there is no evidence of placental infection with SARS-CoV-2. Published reports to date suggest that perinatal transmission of SARSCoV- 2 can occur but is rare. Among 179 newborns tested for SARS-CoV2 at birth from mothers with COVID-19, transmission was suspected in 8 cases, 5 with positive nasopharyngeal SARS-CoV-2 RT-PCR and 3 with SARS-CoV-2 IgM. However, these cases arise from maternal infection close to childbirth and there are no information about exposition during first or second trimester of pregnancy. Welldesigned prospective cohort studies with rigorous judgement criteria are needed to determine the incidence and risk factors for perinatal transmission of SARS-CoV-2. The pandemic due to the emerging coronavirus named SARS-CoV-2 started in China in late 2019 and quickly spread around the world. This virus follows two previous epidemics of severe acute J o u r n a l P r e -p r o o f pneumonitis associated with the coronavirus SARS-CoV-1 and MERS-CoV (N. . The purpose of this review is to report and comment from virologists' and obstetricians' points of view the existing data concerning a possible mother to child transmission of SARS-CoV-2 and its potential consequences on the perinatal and subsequent outcomes. During a primary infection, the passage of virus in the blood even for a short time, is an essential prerequisite for maternal-fetal transmission to occur by the trans-placental route. In previous epidemics of severe acute respiratory syndrome associated with SARS-CoV-1, ± 78% of patients had detectable viral RNA in blood within the week of onset of symptoms. The viremia was determined using a quantitative PCR test specific for the SARS-CoV-1 genome, with a detection limit of 74 copies / ml in plasma. The plasma viral load found in patients with so-called "moderate" symptoms was low with an average concentration of 140 copies / mL, close to the detection threshold (Ng et al. 2003; Grant et al. 2003 ). These SARS-1 studies were carried out with optimized methods, while the optimization of methods to detect viremia is still underway for the SARS-CoV-2 studies (Mahony and Richardson 2005) . In patients with COVID-19, the SARS-CoV-2 virus may be undetectable by PCR tests on oropharyngeal samples. In two cohort studies of 205 and 40 patients, the presence of plasma viral RNA was detected in only 1% and 15% of patients, respectively (W. Wang et al. 2020; Huang et al. 2020 ). Finally, German researchers recently reported the failure to isolate infectious viruses from the blood of infected patients (Wölfel et al. 2020) . The use of more sensitive SARS-CoV-2 PCR tests such as like a recently described assay that detected positive viremia in 11/80 samples from 15 previously negative (0/80) patients should increase the detection rate of the virus in blood as was observed in nasopharyngeal samples (Chan et al. 2020) . This new test allowed to establish in vitro the relationship between infectious virus and number of copies that is now estimated to be 1.8 TCID50 (approximately J o u r n a l P r e -p r o o f 4 infectious particles for 11 copies (95% confidence interval: 7.2-52.6 copies). A very recent submitted article shown that in a cohort of 50 COVID patient, but 78% male, the detection of viremia, using the WHO RT-qPCR protocol, rise significantly from 60% to 88% according to the severity of the disease. (Hadjadj et al. 2020) In this article, the median of plasma viral load was from 100 to 500 copies/mL respectively. However, one patient shown viral load upper than 10 4 copies/mL. These plasma viral load data will be invaluable in assessing the risk of in utero virus transmission when the test becomes available and can be applied to pregnant women blood samples. Of note, using deep sequencing methods the presence of viral RNA has been recently been shown in the mononuclear cells of the bronchoalveolar lavage, but not in those of peripheral blood mononuclear cell (PBMC), in 2 of 3 patients studied . Furthermore, it has been shown in lymphoid lines (MT2 and A3.01) that the virus was able to enter lymphocytes, but these infections were not productive (Xinling Wang et al. 2020 ). Thus, with regards to SARS-CoV-2, the presence of viral RNA in the blood therefore does exist, but at low levels, and its ability to transmit infection is still uncertain. Another study failed to demonstrate viral production following direct infection of blood monocytes with high infectious doses of SARS-CoV-2 virus (MOI 10, i.e. 10 infectious particles / cells) (Wang X et al. 2020) . Conversely, the authors described a gradual decrease in the intracellular amount of RNA over time. These results should however be put into perspective if we consider the experience of Chikungunya for which there is no infection of PBMC in vitro but for which we have been able to repeatedly show the transient presence in monocytes and lymphocytes B in the blood of patients and during ex vivo infection of whole blood in humans, as well as in the macaque model. (Her et al. 2010 ) These data suggest that the frequency and titers of RNAemia in SARS-CoV-2 infected patients may be lower or at most equivalent to that seen in SARS-CoV-1 infected patients. In addition, the virus does not seem capable of developing a productive infection in the circulating monocytes, or at a very low level, in line with previous observations on SARS-CoV-1 (Castilletti et al. 2005) . These results remain to be confirmed once the detection tests in plasma have been optimized. In comparison, another virus of interest in obstetrics, ZIKV is detectable repeatedly or even continuously in the blood of pregnant women (or in animal models) while its presence can only be detected in an acute manner (less than one week) in a non-pregnant woman (Nguyen et al. 2017) . Does placental transmission of SARS-CoV-2 occur? (Figure 1) The second element that might be necessary for a maternal-fetal infection is a placental tropism of the virus i.e. the virus will infect the placental cells and thus be transmitted to the fetal side. To date, no case of placental infection with SARS-CoV-2, has been reported. In five publications, a total of 7 placentas delivered from COVID-19 patients were studied using RT-PCR ; SARS-CoV-2 was not found in any of them (S. Xiaotong Wang et al. 2020; Yu, Li, Kang, Xiong, et al. 2020; S. Wang et al. 2020) . Furthermore, histopathological analysis of three placentas did not reveal any significant lesion. (S. The hypothesis of a lack of placental infection is reinforced by the fact that the receptor for SARS-CoV-2, the angiotensin 2 converting enzyme (ACE2) necessary for its cell integration, is present only at very low levels in the human placenta during the first third trimester of pregnancy (Zheng n.d.) , while there are no data on the expression of this receptor in 2nd and 3rd trimester) placentas. However, in a hypertensive rat model induced by a saline diet, expression (mRNA) and significant enzymatic activity of the ACE2 receptor was observed in the uterus and the placenta in late gestation (day 19-20) . Thus, the possibility of placental infection near delivery and therefore a potential passage to the fetus infection that required further investigation. (Levy et al. 2008 ). Another way for the virus to cross the barrier is to be carried by an infected blood cell. However, SARS-CoV-2, if able to enter into PBMCs does not seem to be replicative in these cells, like SARS-CoV-1 ). On the other hand, the resident macrophages of the lymph nodes or the spleen would express the ACE2 receptor (ACE2 +, CD169 + or CD68 + cells) and in terminally ill patients, the virus is found in these cells (Immunohistochemistry, nucleocapsid) but not in T or B lymphocytes J o u r n a l P r e -p r o o f (Y. ). SARS-CoV-1, which also uses the ACE2 receptor, is also found in alveolar macrophages (P. C.-H. Chen and Hsiao 2004) . Although no replication or transport of infectious viruses by macrophage monocytes has been demonstrated, nonetheless lymph node and spleen macrophages can harbor the virus. This underlines the need to analyze Hofbauer cells, the macrophages residing in the decidua and the placenta. Another mechanism for viral transmission through the placenta is transcytosis of opsonized or free virus as has been shown for HIV, but this remains very hypothetical in view of the low viremia mentioned above (Lagaye et al. 2001) . Alzamora et al. 2020; Yan et al. 2020) . All of the patients were infected in late pregnancy and delivered within a few days of infection (mean: 3 days, range: 0 to 25 days). PCRs were performed on amniotic fluid and on cord blood during respectively 37 and 48 of these deliveries, all of which were negative. (Table 1) Among the 179 newborns, SARS-CoV-2 was detected in nasopharyngeal samples from six of them, one at 16 hours of life, two at 36 hours of life and three at 48 hours of life. Thus, the timing of transmission cannot be determined in these cases. Transmission may have occurred after birth via the inhalation of droplets produced by contaminated parents or professionals, or via breastfeeding. The authors state that the infants were delivered by cesarean section and immediately separated from their mothers and placed in isolation, suggesting that postnatal transmission by the mother was unlikely. (Table 2 and (Malek et al. 1996) . However, whether this is evidence of in utero transmission has been disputed (Kimberlin and Stagno 2020) . The sensitivity / specificity of IgM detection would be 88.2% / 96.2% and 70.2% / 99% according to these same studies and thus much higher than that observed for other viral infections. Furthermore, none of this children had a positive RT-PCR in nasopharyngeal samples (H. Dong et al. 2020 ) nor in the blood (H. ). In addition, the decrease in IgM is very rapid in the Dong L study, going from 45.83 AU / mL to 2 hours of life compared to 11.75 AU / mL on the 14th day of life (for a positivity threshold of 10 AU / mL), which seems surprising in the case of a congenital infection J o u r n a l P r e -p r o o f Although the majority of children born to infected mothers did not seem to have any symptoms, three of them nevertheless presented with severe pneumonia linked to SARS-CoV-2(L. . In these three children the possibility of perinatal or postnatal transmission is unlikely since they were born by cesarean section and were separated from their mother from birth. In the perinatal period, maternal SARS-CoV-2 infection can have harmful consequences on obstetric outcomes and on newborns, resulting in particular in respiratory distress, biological abnormalities, premature deliveries and even fetal death in utero (Y. . The authors hypothesize that hypoxemia in the mother may be responsible for fetal hypoxia at birth and premature delivery. Finally, rare cases of very severe infection have been described in very young children (Cui et al. 2020 ), suggesting that infants may not be very susceptible to COVID-19. There are still no data on a maternal SARS-CoV-2 infection in the 1st and 2nd trimester of pregnancy, including the risk of early miscarriage, fetal death in utero and growth retardation. A single study do not find viral RNA in amniotic fluid in mid-pregnancy on two patients exposed in the first trimester. (Yu, Li, Kang, Zeng, et al. 2020) A study published in 2004 during the SARS epidemic found a higher rate of miscarriage, premature delivery and stunting, but no argument for vertical transmission (Wong et al. 2004 ). In addition, abnormally high mortality was not observed in pregnant women infected with SARS-CoV-2, compared to what had been observed during the epidemics SARS-CoV-1 and MERS-CoV (Schwartz 2020) . No fetopathy has been described to date in fetuses or neonates whose mothers had COVID-19. In summary, current data fail to demonstrate maternal-fetal transmission, but are largely incomplete. According to these data, the transmission risk is probably very low, possibly under 1% following maternal SARS-CoV-1 infection during pregnancy. The available studies concerned patients infected at the end of pregnancy, and in these studies, it should be noted that the time between J o u r n a l P r e -p r o o f maternal infection and delivery was often very short (of the order of a few days), which may not be sufficient for transplacental passage to occur. women and the risk of in utero transmission. Prospective cohort studies should be able to answer the following important questions : -What is the impact of SARS CoV-2 on maternal and pregnancy outcomes according to the period of infection in pregnancy, the severity and management, including therapies ? -What are the proportions with viral replication and its duration in the nasopharyngeal tract, intestine and maternal blood ? -What are the risks of mother-to-child during the pregnancy, during labor and vaginal delivery and postnatally, in children who are not separated from the mother, as is common practice in most settings outside of China. In parallel, in vitro or ex vivo studies are needed to determine whether the virus infects and is produced by decidual or placental cells. The answers to these questions will determine how to revise current recommendations (Peyronnet et al. 2020) for the care of COVID-19 pregnant women and their neonates in the future. The authors report no potential conflicts. Table 1 : Maternal and neonatal characteristics from published studies (only case for which newborn were tested for SARS-CoV-2 have been reported). If some samples are not mentioned, they have been considered as not performed. 1 Only two patients were tested. 2 Only one placenta was tested 3 The mother of the twins had typical clinical symptoms, and viral interstitial pneumonia was revealed by a CT scan of her chest. Although her nasopharyngeal swab returned a negative result, other diseases that could cause fever and lung infection were excluded. The local CDC then registered her as a confirmed 2019-nCoV case 4 One prelevement was positive 3 days after delivery. 5 One twin pregnancy. 6 Only the infected newborn was tested. 7 Only stated for the 3 positive newborns. 8 Only ten patients were laboratory-confirmed with COVID-19. According to the study, a clinically diagnosed COVID-19 case was defined as a case of pneumonia that fullfilled the following four criteria -fever and/or respiratory symptoms; radiographic evidence of typical viral pneumonia (bilateral ground-glass opacities); low or normal white-cell count or low lymphocyte count; and no improvement in symptoms after antimicrobial treatment for 2 days, ruling out common virus infection like influenza with or without an epidemiologic link to the Huanan Seafood Wholesale Market or contact with other patients with similar symptoms. Strict infection control and prevention procedures were implemented during the delivery The mother had been wearing an N95 mask throughout the operation, and the baby had no contact with the mother after birth. The infant was transferred to neonatology department 10 minutes after birth for close observation and the mother was transferred to the fever ward for isolation after surgery. He was immediately separated from his mother and was not exposed to family members, who were at home under strict isolation measures. Due to the maternal condition, maternal medical regimen, breastfeeding was not initiated. He was placed in the neonatal intensive care unit (NICU) with no other COVID-19 cases. After ceasarean section, a 3250g newborn was managed without neonatal complications. The neonate had no fever and cough, with mild shortness of breath. symptoms. Chest x-ray revealed mild pulmonary infection. The shortness of breath relieved quickly under neonatal care and monitoring. The neonate was discharged after 2 weeks following two consecutive negative nucleic acid test results. On day 2 of life, the infant experienced lethargy and fever, with unremarkable physical examination results, and was moved to the neonatal intensive care unit. A chest radiographic image showed pneumonia, but other laboratory tests. (except procalcitonin) were normal. Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 6 He presented with lethargy, vomiting, and fever. A physical examination was unremarkable. Labora-tory tests showed leukocytosis, lymphocytopenia, and an elevated creatine kinase-MB fraction. A chest radiographic image showed pneumonia. Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 6 Resuscitation was required. The infant's Apgar scores were 3, 4, and 5 at 1, 5, and 10 minutes after birth. Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation, caffeine, and antibiotics. He also had suspected sepsis, with an Enterobacter agglomerates-positive blood culture, leukocytosis, thrombocytopenia (11 cells × 103/μL; to convert to cells × 109/L, multiply by 1.0), and coagulopathy (prothrombin time, 21 seconds; acti-vated partial thromboplastin time, 81.9 seconds), which improved with antibiotic treatment. Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 7 a baby boy was delivered, weighted 3205g. Apgar scores at 1 and 5 minutes were 8 and 9. The infant had no moaning or spitting after birth. The skin was ruddy and the crying was loud. Half an hour after birth, the infant vomitted once after feeding formula, which we considered to be swallowing syndrome. After gastric lavage, the infant could be fed normally. Blood tests of the neonate revealed lymphopenia, deranged liver function tests and elevated creatine kinase level. Intravenous penicillin G and vitamin K1 were given as antibiotic prophylaxis and to prevent coagulopathy, respectively. The neonate weighed 2,970 g, with Apgar's scores of 6 and 8 at 1 and 5 minutes, respectively. The neonate was intubated in another room due to the high level of sedation of the mother. The newborn required ventilatory support for 12 hours, after which he was extubated and placed on continuous positive airway pressure, with favorable outcome and not requiring antibiotic treatment. At the sixth day of life, the newborn presented mild respiratory difficulty and sporadic cough requiring supplemental oxygen with nasal cannula. Imaging and laboratory testing remain normal. Severe COVID-19 during Pregnancy and Possible Vertical Transmission COVID-19 Infection among Asymptomatic and Symptomatic Pregnant Women: Two Weeks of Confirmed Presentations to an Affiliated Pair of New York City Hospitals Coordinate Induction of IFNα and -γ by SARS-CoV Also in the Absence of Virus Replication Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay Validated in Vitro and with Clinical Specimens Clinical Characteristics and Intrauterine Vertical Transmission Potential of COVID-19 Infection in Nine Pregnant Women: A Retrospective Review of Medical Records Tissue and Cellular Tropism of the Coronavirus Associated with Severe Acute Respiratory Syndrome: An in-Situ Hybridization Study of Fatal Cases The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes A 55-Day-Old Female Infant Infected with COVID 19: Presenting with Pneumonia, Liver Injury, and Heart Damage Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn Detection of SARS Coronavirus in Plasma by Real-Time RT-PCR Impaired Type I Interferon Activity and Exacerbated Inflammatory Responses in Severe Covid-19 Patients Active Infection of Human Blood Monocytes by Chikungunya Virus Triggers an Innate Immune Response Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China Can SARS-CoV-2 Infection Be Acquired In Utero?: More Definitive Evidence Is Needed Cell-to-Cell Contact Results in a Selective Translocation of Maternal Human Immunodeficiency Virus Type 1 Quasispecies across a Trophoblastic Barrier by Both Transcytosis and Infection ACE2 Expression and Activity Are Enhanced during Pregnancy Clinical Characteristics of 19 Neonates Born to Mothers with COVID-19 Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case Series Clinical Manifestations and Outcome of SARS-CoV-2 Infection during Pregnancy Molecular Diagnosis of Severe Acute Respiratory Syndrome Evolution of Maternofetal Transport of Immunoglobulins during Human Pregnancy Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome Highly Efficient Maternal-Fetal Zika Virus Transmission in Pregnant Rhesus Macaques SARS-CoV-2 infection during pregnancy. Information and proposal of management care Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Detection of SARS-CoV-2 in Different Types of Clinical Specimens Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America SARS-CoV-2 Infects T Lymphocytes through Its Spike Protein-Mediated Membrane Fusion Virological Assessment of Hospitalized Patients with COVID-2019 Pregnancy and Perinatal Outcomes of Women with Severe Acute Respiratory Syndrome Transcriptomic Characteristics of Bronchoalveolar Lavage Fluid and Peripheral Blood Mononuclear Cells in COVID-19 Patients Coronavirus Disease 2019 (COVID-19) in Pregnant Women: A Report Based on 116 Cases Clinical Characteristics and Risk Assessment of Newborns Born to Mothers with COVID-19 Clinical Features and Obstetric and Neonatal Outcomes of Pregnant Patients with COVID-19 in Wuhan, China: A Retrospective, Single-Centre, Descriptive Study No SARS-CoV-2 Detected in Amniotic Fluid in Mid-Pregnancy Antibodies in Infants Born to Mothers With COVID-19 Pneumonia Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China Single-Cell RNA Expression Profiling of ACE2 and AXL in the Human Maternal-Fetal Interface Clinical Analysis of 10 Neonates Born to Mothers with 2019-NCoV Pneumonia A Novel Coronavirus from Patients with Pneumonia in China The authors thank Dr. Elisabeth Menu for critical reading of the manuscript. Maternal clinical characteristics All 6mothers had mild clinical manifestations. All had cesarean deliveries in their third trimester.A primiparous woman suspected of being exposed to SARS-CoV-2 developed a temperature of 37.9° C and nasal congestion, which progressed to respiratory difficulties. A chest CT showed patchy ground-glass opacities in the periphery of both lungs. The RT-PCR on a nasopharyngeal swab was positive. The patient was admitted to RenminHospital and received antiviral, antibiotic, corticosteroid, and oxygen therapies. All had deliveries in negative pressure isolation rooms. All mothers wore masks, and all medical staff wore protective suits and double masks. The infants were isolated from their mothers immediately after deliveryAn infant girl was delivered in a negative-pressure isolation room. The mother wore an N95 mask and did not hold the infant. The infant was immediately quarantined in the neonatal intensive care unit. All 6 infants had 1-minute Apgar scores of 8 to 9 and 5-minute Apgar scores of 9 to 10. None of the infants presented any symptoms.1 Her birth weight was 3120 g and Apgar scores were 9 at 1 minute and 10 at 5 minutes. The neonate had no symptoms. Negative Negative Negative Neonatal RT-PCR in placenta NA NA NP Negative Negative NP Positive IgG level of 125.5AU/mL (reference range < 10) andIgM level of 39.6 AU/mL (reference range < 10) Positive IgG level of 113.91 AU/mL (reference range < 10) and IgM level of 16.25 AU/mL (reference range < 10) Positive At 2 hours of age, the SARS-CoV-2 IgG level was 140.32 AU/mL and the IgM level was 45.83 AU/mL. Her IgM (11.75 AU/mL) and IgG (69.94 AU/mL) levels were still elevated on March 7 (reference range < 10), and she was discharged on March 18.